脳血栓除去デバイスの世界市場：2023-2030年

世界の脳血栓除去デバイス市場は、予測期間（2023-2030年）にCAGR 7.3％で成長すると予測されています。この市場の成長は、急性虚血性脳卒中の世界の発生率の増加、不健康な生活習慣の採用率の上昇、人口の間での障害に対する意識の高まりが市場成長を促進していることに起因しています。世界脳卒中機構ファクトシート2022によると、全年齢の虚血性脳卒中の有病率は7,630,803でした。年間10万人当たりの粗発生率は94.5、年間10万人当たりの年齢調整率は98.6でした。虚血性脳卒中は毎年760万人以上が新たに発症しています。世界全体では、脳卒中発症の62.0％以上が虚血性脳卒中です。そのうち、毎年、虚血性脳卒中全体の11％以上が15～49歳で発症し、虚血性脳卒中全体の58.0％以上が70歳未満で発症し、虚血性脳卒中全体の45.0％が男性で発症し、虚血性脳卒中全体の55.0％が女性で発症しています。また、2022年11月には、「高齢者人口統計：A Portrait of Aging Americans」では、米国人口の16.3％にあたる5,410万人が65歳以上の高齢者であると報告されています。高齢者人口は2040年までに22.0％、2060年までに25.0％に増加すると予想されています。

セグメント別展望

血栓回収デバイスは脳血栓除去デバイスの世界市場で大きなシェアを占めると予測される

製品の中では、血栓回収デバイスのサブセグメントが予測期間中に成長すると予測されています。このセグメントは、AISの有病率の上昇と主要市場プレーヤーによる製品発売の増加によって牽引されています。血栓回収装置は、主に脳動脈から血栓を除去するために使用されます。さらに、脳梗塞の罹患率の増加により、血栓回収器の使用は高齢者（55～65歳）で増加しています。従って、対象となる疾患の症例が増加していることが、同分野の成長を牽引しています。また、FDAの承認件数の増加がセグメントの成長を加速させています。2023年6月、Innova Vascular, Inc.は、Laguna Clot Retriever（TM）システムとMalibu Aspiration Catheter（TM）システムの末梢血管用として米国食品医薬品局（FDA）510（k）認可を取得しました。この2つの新しい装置は総称してラグナ血栓除去システムと呼ばれています。

地域別展望

世界の脳血栓除去デバイス市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋地域（インド、中国、日本、韓国、その他アジア地域）、その他世界のその他の地域（中東とアフリカ、中南米）を含む地域別にさらに細分化されています。なかでも、アジア太平洋地域は予測期間中に大きく成長すると予想されています。これは、脳血栓除去デバイスに対する需要の増加、老年人口の増加、医療支出の増加、心血管疾患（CVDs）や心臓関連疾患の増加によるものです。

北米地域は脳血栓除去デバイスの世界市場で大幅なCAGRで成長する見込み

北米は予測期間中、脳血栓除去デバイス市場で顕著なシェアを占めると予測されています。北米市場を刺激する重要な要因としては、脳血栓除去デバイスの技術的進歩の拡大、脳卒中の発生率の上昇、老人人口の増加、モニタリング装置に関する政府の有利な規制などが挙げられます。米国国勢調査局によると、高齢者人口は1920年の490万人（米国総人口の4.7％）から2020年には5,580万人（16.8％）へと5,090万人増加します。2020年には、米国の約6人に1人が65歳以上となります。1920年には、この割合は20人に1人以下でした。さらに、脳血栓除去デバイスや、CVDの予防と管理を確実に向上させるためのその他の技術的進歩に対する需要は、今後増加すると思われます。米国心臓協会によると、CVDは依然として米国における主要な死因であり、2020年には928,741人が死亡すると予測されています。さらに、心臓関連疾患の増加と技術の進歩が、この地域の市場をさらに牽引しています。米国における2020年のCVDに起因する死因の第1位は冠動脈性心疾患（CHD）で（41.2%）、第2位は脳卒中（17.3%）でした。

目次

第1章 レポート概要

• 業界の現状分析と成長ポテンシャルの展望
• 調査方法とツール
• 市場内訳
  • セグメント別
  • 地域別

第2章 市場概要と洞察

• 調査範囲
• アナリストの洞察と現在の市場動向
  • 主な調査結果
  • 推奨事項
  • 結論

第3章 競合情勢

• 主要企業分析
• Acandis GmbH
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Medtronic plc
  • 会社概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Penumbra, Inc.
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Stryker Corp.
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• 主要戦略分析

第4章 市場セグメンテーション

• 脳血栓除去デバイスの世界市場：製品別
  • 血栓回収デバイス
  • 吸引デバイス
  • 血管内スネア
• 脳血栓除去デバイスの世界市場：エンドユーザー別
  • 病院
  • 救急クリニック

第5章 地域別分析

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • スペイン
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 世界のその他の地域

第6章 企業プロファイル

• Abbott Laboratories
• Acandis GmbH
• ARGON MEDICAL
• Boston Scientific Corp.,
• Edwards Lifesciences Corp.,
• INARI Medical
• Johnson & Johnson Pvt Ltd
• Koninklijke Philips N.V.
• Microport Scientific Corp.,
• Penumbra, Inc.
• Phenox GmbH
• Siemens Healthineers
• Teleflex Inc.,
• Terumo Corp.,
• Vesalio, LLC
• W.L. Gore & Associatess, Inc.

LIST OF TABLES

• 1. GLOBAL NEUROTHROMBECTOMY DEVICES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
• 2. GLOBAL CLOT RETRIEVERS NEUROTHROMBECTOMY DEVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 3. GLOBAL ASPIRATION NEUROTHROMBECTOMY DEVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 4. GLOBAL VASCULAR SNARES NEUROTHROMBECTOMY DEVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 5. GLOBAL NEUROTHROMBECTOMY DEVICES MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
• 6. GLOBAL NEUROTHROMBECTOMY DEVICES FOR HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 7. GLOBAL NEUROTHROMBECTOMY DEVICES FOR EMERGENCY CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 8. GLOBAL NEUROTHROMBECTOMY DEVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 9. NORTH AMERICAN NEUROTHROMBECTOMY DEVICES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 10. NORTH AMERICAN NEUROTHROMBECTOMY DEVICES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
• 11. NORTH AMERICAN NEUROTHROMBECTOMY DEVICES MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
• 12. EUROPEAN NEUROTHROMBECTOMY DEVICES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 13. EUROPEAN NEUROTHROMBECTOMY DEVICES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
• 14. EUROPEAN NEUROTHROMBECTOMY DEVICES MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
• 15. ASIA-PACIFIC NEUROTHROMBECTOMY DEVICES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 16. ASIA-PACIFIC NEUROTHROMBECTOMY DEVICES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
• 17. ASIA-PACIFIC NEUROTHROMBECTOMY DEVICES MARKET RESEARCH AND ANALYSIS BY END-USER,2022-2030 ($ MILLION)
• 18. REST OF THE WORLD NEUROTHROMBECTOMY DEVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 19. REST OF THE WORLD NEUROTHROMBECTOMY DEVICES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
• 20. REST OF THE WORLD NEUROTHROMBECTOMY DEVICES MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

• 1. GLOBAL NEUROTHROMBECTOMY DEVICES MARKET SHARE BY PRODUCT, 2022 VS 2030 (%)
• 2. GLOBAL CLOT RETRIEVERS NEUROTHROMBECTOMY DEVICES MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 3. GLOBAL ASPIRATION NEUROTHROMBECTOMY DEVICES MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 4. GLOBAL VASCULAR SNARES NEUROTHROMBECTOMY DEVICES MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 5. GLOBAL NEUROTHROMBECTOMY DEVICES MARKET RESEARCH AND ANALYSIS BY END-USER, 2022 VS 2030 (%)
• 6. GLOBAL NEUROTHROMBECTOMY DEVICES FOR HOSPITALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 7. GLOBAL NEUROTHROMBECTOMY DEVICES FOR EMERGENCY CLINICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 8. GLOBAL NEUROTHROMBECTOMY DEVICES MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 9. US NEUROTHROMBECTOMY DEVICES MARKET SIZE, 2022-2030 ($ MILLION)
• 10. CANADA NEUROTHROMBECTOMY DEVICES MARKET SIZE, 2022-2030 ($ MILLION)
• 11. UK NEUROTHROMBECTOMY DEVICES MARKET SIZE, 2022-2030 ($ MILLION)
• 12. FRANCE NEUROTHROMBECTOMY DEVICES MARKET SIZE, 2022-2030 ($ MILLION)
• 13. GERMANY NEUROTHROMBECTOMY DEVICES MARKET SIZE, 2022-2030 ($ MILLION)
• 14. ITALY NEUROTHROMBECTOMY DEVICES MARKET SIZE, 2022-2030 ($ MILLION)
• 15. SPAIN NEUROTHROMBECTOMY DEVICES MARKET SIZE, 2022-2030 ($ MILLION)
• 16. REST OF EUROPE NEUROTHROMBECTOMY DEVICES MARKET SIZE, 2022-2030 ($ MILLION)
• 17. INDIA NEUROTHROMBECTOMY DEVICES MARKET SIZE, 2022-2030 ($ MILLION)
• 18. CHINA NEUROTHROMBECTOMY DEVICES MARKET SIZE, 2022-2030 ($ MILLION)
• 19. JAPAN NEUROTHROMBECTOMY DEVICES MARKET SIZE, 2022-2030 ($ MILLION)
• 20. SOUTH KOREA NEUROTHROMBECTOMY DEVICES MARKET SIZE, 2022-2030 ($ MILLION)
• 21. REST OF ASIA-PACIFIC NEUROTHROMBECTOMY DEVICES MARKET SIZE, 2022-2030 ($ MILLION)
• 22. REST OF THE WORLD NEUROTHROMBECTOMY DEVICES MARKET SIZE, 2022-2030 ($ MILLION)

Global Neurothrombectomy Devices Market Size, Share & Trends Analysis Report by Product (Clot Retrievers Devices, Aspiration Devices, and Vascular Snares), and by End-User (Hospitals and Emergency Clinics), Forecast Period (2023-2030)

The global neurothrombectomy devices market is anticipated to grow at a CAGR of 7.3% during the forecast period (2023-2030). The growth of this market is attributed to the increasing incidences of acute ischemic stroke globally, rising adoption of unhealthy lifestyles and increasing awareness of the disorder among the population is fueling market growth. According to the World Stroke Organization Fact Sheet 2022, Prevalence for all Ischemic stroke for all ages were 7,630,803. The crude rate per 100,000 per year was 94.5, and Age-adjusted rate per 100,000, per year was 98.6. There are over 7.6 million new ischemic strokes each year. Globally, over 62.0% of all incident strokes are ischemic strokes. Of which, each year, over 11% of all ischemic strokes occur in people 15-49 years of age, over 58.0% of all ischemic strokes occur in people aged under 70 years, 45.0% of all ischemic strokes occur in men, and 55.0% of all ischemic strokes occur in women. In addition, in November 2022, the article "Senior Population Statistics: A Portrait of Aging Americans", reported 54.1 million adults or 16.3% of the US population are seniors including aged 65 or older. The senior population is expected to rise to 22.0% by 2040 and 25.0% by 2060.

Segmental Outlook

The global neurothrombectomy devices market is segmented based on product and end-user. Based on the product, the market is sub-segmented into clot retrievers devices, aspiration devices, and vascular snares. Further, based on end-user, the market is bifurcated into hospitals and emergency clinics. Among the end-user, the hospitals sub-segment is anticipated to hold the largest market share during the forecast period. The large share of this segment is credited to the lower costs, higher efficiency, and availability.

The Clot Retrievers Devices Sub-Segment is Anticipated to Hold a Considerable Share of the Global Neurothrombectomy Devices Market

Among the products, clot retrievers devices sub-segments expected to grow over the forecast period. The segment is driven by the owing to rising prevalence of AIS and an increasing number of product launches by key market players. It is majorly used for removing blood clots from the cerebral arteries. Furthermore, the use of clot retrievers has increased in elderly patients (aged 55 to 65) owing to growing incidence of stroke. Hence, growing cases of targeted disorder are driving segment growth. In addition, the growing number of FDA approvals is accelerating the segmental growth. In June 2023, Innova Vascular, Inc. received US Food and Drug Administration (FDA) 510(k) clearance for its Laguna Clot Retriever™ System and its Malibu Aspiration Catheter™ System for use in the peripheral vasculature. The two new devices are collectively known as the Laguna Thrombectomy System.

Regional Outlook

The global neurothrombectomy devices market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, the Asia-Pacific region is anticipated to grow considerably over the forecast period. This is owing to the growing demand for neurothrombectomy devices, increasing geriatric population, the rising healthcare expenditure, and increasing incidences of cardiovascular diseases (CVDs) and heart related conditions.

The North America Region is Expected to Grow at a Significant CAGR in the Global Neurothrombectomy Devices Market

North America is expected to hold a prominent share in the neurothrombectomy devices market during the forecast period. The significant factors fueling the North America market including growing technological advancements in neurothrombectomy devices, rising incidences of strokes, increasing geriatric population, and favorable government regulations regarding monitoring devices. According to the United States Census Bureau, the older population increased by 50.9 million, from 4.9 million (or 4.7% of the total US population) in 1920 to 55.8 million (16.8%) in 2020. In 2020, about 1 in 6 people in the US were age 65 and over. In 1920, this proportion was less than 1 in 20. In addition, the demand for neurothrombectomy devices, and other technological advancements to ensure improved CVD prevention and control is likely to rise in the future. According to the American Heart Association, CVDs remains as the leading cause of death in the US, accounted for 928,741 deaths in the year 2020. Additionally, the increasing number of heart-related disorders and technological advancements are further driving the market in the region. In 2020 in the US, coronary heart disease (CHD) was the leading cause (41.2%) of deaths attributable to CVD in the US, followed by stroke (17.3%).

Market Players Outlook

The major companies serving the global neurothrombectomy devices market includes Acandis GmbH, Medtronic plc, Penumbra, Inc., and Stryker Corp., among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in July 2023, RenovoRx, Inc., a Los Altos, California-based clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd, a clinical-stage immuno-oncology company headquartered in Sydney, Australia, entered a strategic research collaboration to optimize the delivery of Imugene's oncolytic virus therapy with RenovoRx's trans arterial micro perfusion (TAMP) therapy platform for the treatment of difficult-to-access tumors. As part of the collaboration, Imugene and RenovoRx will investigate the ability to administer Imugene's CF33 oncolytic virus technology with RenovoRx's TAMP therapy platform.

The Report Covers:

• Market value data analysis of 2022 and forecast to 2030.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global neurothrombectomy devices market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. Acandis GmbH
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Medtronic plc
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. Penumbra, Inc.
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Stryker Corp.
  • 3.5.1. Overview
  • 3.5.2. Financial Analysis
  • 3.5.3. SWOT Analysis
  • 3.5.4. Recent Developments
• 3.6. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global Neurothrombectomy Devices Market by Product
  • 4.1.1. Clot Retrievers Devices
  • 4.1.2. Aspiration Devices
  • 4.1.3. Vascular Snares
• 4.2. Global Neurothrombectomy Devices Market by End-User
  • 4.2.1. Hospitals
  • 4.2.2. Emergency Clinics

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World

6. Company Profiles

• 6.1. Abbott Laboratories
• 6.2. Acandis GmbH
• 6.3. ARGON MEDICAL
• 6.4. Boston Scientific Corp.,
• 6.5. Edwards Lifesciences Corp.,
• 6.6. INARI Medical
• 6.7. Johnson & Johnson Pvt Ltd
• 6.8. Koninklijke Philips N.V.
• 6.9. Microport Scientific Corp.,
• 6.10. Penumbra, Inc.
• 6.11. Phenox GmbH
• 6.12. Siemens Healthineers
• 6.13. Teleflex Inc.,
• 6.14. Terumo Corp.,
• 6.15. Vesalio, LLC
• 6.16. W.L. Gore & Associatess, Inc.